Korean J Med.
2014 Feb;86(2):242-246.
Acute Myeloid Leukemia with Persistent Marrow Aplasia after Chemotherapy Treated with Reduced-Intensity Allogeneic Stem Cell Transplantation
- Affiliations
-
- 1Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea. alertjun@hanmail.net
- 2Department of Laboratory Medicine, Gachon University School of Medicine, Incheon, Korea.
Abstract
- Persistent bone marrow aplasia after intensive chemotherapy is uncommon, but is one of the fatal complications in patients with acute myeloid leukemia (AML). Although allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be contraindicated for patients who have hematologic diseases with serious infections, such as bacterial septicemia or invasive fungal diseases, combined with prolonged neutropenia due to frequent morbidity and mortality, such risks can be overcome by non-myeloablative conditioning and best supportive care. Here, we report an AML patient with persistent marrow aplasia after induction therapy, treated successfully with reduced-intensity allogeneic HSCT despite severe bacterial and fungal infections.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The impact of COVID-19 on acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: a concise review
- A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML
- Long-Term Complete Remission in an Acute Myeloid Leukemia Patient with Isolated Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
- Two Cases of Generalized Vitiligo after Allogeneic Stem Cell Transplantation
- A Case of Ovarian-Relapse Sparing of the Marrow in a Patient with Acute T Cell Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
